

Structural and Co-Conformational Effects of Alkyne-Derived Subunits in Charged Donor-Acceptor [2]Catenanes

Ognjen Š. Miljanić,[†] William R. Dichtel,^{†,‡} Saeed I. Khan,[†] Shahab Mortezaei,[†]
James R. Heath,[‡] and J. Fraser Stoddart^{†*}

[†] *California NanoSystems Institute and Department of Chemistry and Biochemistry,
University of California, Los Angeles, 405 Hilgard Avenue, Los Angeles, California 90095*


[‡] *Division of Chemistry and Chemical Engineering, California Institute of Technology,
1200 East California Boulevard, Pasadena, CA 91125*

Supporting Information REVISED VERSION

| Correspondence Address |
|---|
| Professor J Fraser Stoddart California NanoSystems Institute and Department of Chemistry and Biochemistry University of California, Los Angeles 405 Hilgard Avenue Los Angeles, CA 90095-1569 (USA) Tel: (+1)-310-206-7078 Fax: (+1)-310-206-1843 Email: stoddart@chem.ucla.edu |

General Methods. All reagents were purchased from commercial suppliers (Aldrich or Fisher) and used without further purification. Cyclobis(paraquat-*p*-phenylene) hexafluorophosphate^{S1} (**CBPQT** · 4PF₆), 1,5-bis[2-(2-hydroxyethoxy)ethoxy] naphthalene^{S2} (**6a**), 1,5-bis[2-(2-(2-hydroxyethoxy)ethoxy)ethoxy]naphthalene^{S3} (**6b**), 1,5-bis[2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy]naphthalene^{S3} (**6c**) and mono-tosylates^{S4,S5} of **6a** (**S1**) and **6b** were prepared according to literature procedures. Preparation and characterization of catenanes **1b** · 4PF₆ and **2b** · 4PF₆, and their precursors **7b**, **8b**, and **9b** was reported in a previous publication.^{S6} Thin layer chromatography (TLC) was performed on silica gel 60 F₂₅₄ (E. Merck). Column chromatography was performed on silica gel 60F (Merck 9385, 0.040–0.063 mm). Melting points were recorded on an Electrothermal 9100 instrument in open capillary tubes and are uncorrected. Routine nuclear magnetic resonance (NMR) spectra were recorded at 25 °C on a Bruker Avance 400 and 500 spectrometers, with working frequencies of 400 and 500 MHz for ¹H, and 100 and 125 MHz for ¹³C nuclei respectively. VT-NMR spectra were recorded on a Bruker Avance 500 spectrometer and temperature-calibrated using neat MeOH (for *T* < 295 K) and ethylene glycol (for *T* > 295 K). Chemical shifts are reported in ppm relative to the signals corresponding to the residual non-deuterated solvents (CDCl₃: δ 7.26 ppm, CD₃CN: δ 1.93 ppm, DMF-*d*₇: δ 8.01 ppm). All ¹³C spectra were recorded with the simultaneous decoupling of proton nuclei. Fast atom bombardment mass spectra were obtained on a JEOL JMS-600H high resolution mass spectrometer equipped with a FAB probe.


Scheme S1. Synthesis of DNP Azide Derivative **7a**.



A solution of tosylate^{S4} **S1** (1.37 g, 2.78 mmol) and NaN₃ (904 mg, 13.9 mmol) in dry DMF (15 mL) was heated at 80 °C for 20 h. After cooling, the solvent was removed in

vacuo. The resulting brown oil was redissolved in CH₂Cl₂, and washed first with 1M aqueous HCl solution, followed by sat. aqueous NaHCO₃ solution. After drying (MgSO₄) and removal of the solvent, the crude product was subjected to chromatography on silica (EtOAc → EtOAc/Me₂CO = 50/50) to provide 380 mg of **7a** as a viscous yellow oil (38%). **7a**: MS (FAB+): *m/z* (rel intensity) = 361 (M⁺, 100%), 227 (39), 160 (36), 149 (79). ¹H NMR (500 MHz, CDCl₃): δ 7.89 (d, ³*J* (H,H) = 8.2 Hz, 1H), 7.87 (d, ³*J* (H,H) = 8.2 Hz, 1H), 7.35 (t, ³*J* (H,H) = 8.2 Hz, 1H), 7.35 (t, ³*J* (H,H) = 8.2 Hz, 1H), 6.82 (d, ³*J* (H,H) = 8.2 Hz, 1H), 6.80 (d, ³*J* (H,H) = 8.2 Hz, 1H), 4.28–4.20 (m, 4H), 3.96–3.90 (m, 4H), 3.78–3.76 (m, 2H), 3.75–3.72 (br m, 2H), 3.68–3.65 (m, 2H), 3.39 (t, ³*J* (H,H) = 5.0 Hz, 2H), 2.62 (br s, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 154.16 (2C), 126.65, 126.63, 125.15, 125.07, 114.60, 114.48, 105.70, 105.68, 72.58, 70.22, 69.69, 69.58, 67.82, 67.76, 61.64, 50.67. HRMS Calcd for C₁₈H₂₃N₃O₅: 361.1638. Found: 361.1649.


Scheme S2. Synthesis of DNP Monotosylate **S2**.



The diol **6c** (1.38 g, 2.69 mmol), NEt₃ (555 mg, 780 μL, 5.50 mmol), and DMAP (20 mg, 0.16 mmol) were dissolved in CH₂Cl₂ (50 mL). A solution of TsCl (514 mg, 2.71 mmol) in CH₂Cl₂ (18 mL) was added dropwise to this mixture during 12 h at 23 °C (syringe pump, 1.5 mL/h). After the addition was complete, the reaction mixture was left to stir at 23 °C for 4 additional h. It was then washed with sat. aqueous NaHCO₃ solution and brine and dried (MgSO₄). Column chromatography (CH₂Cl₂ → EtOAc) isolated, in order of elution, the ditosylate^{S3} of **6c** (310 mg, 17%), followed by **S2** (780 mg, 44%), and unreacted starting material (400 mg, 29%). **S2**: MS (FAB+): *m/z* (rel intensity) = 666 (M⁺, 100%). ¹H NMR (400 MHz, CDCl₃): δ 7.75 (d, ³*J* (H,H) = 8.4 Hz, 1H), 7.74 (d, ³*J* (H,H) = 8.4 Hz, 1H), 7.61 (d, ³*J* (H,H) = 8.0 Hz, 2H), 7.21 (t, ³*J* (H,H) = 8.4 Hz, 1H), 7.21 (t, ³*J* (H,H) =


8.4 Hz, 1H), 7.12 (d, 3J (H,H) = 8.0 Hz, 2H), 6.68 (d, 3J (H,H) = 8.4 Hz, 1H), 6.68 (d, 3J (H,H) = 8.4 Hz, 1H), 4.11–4.07 (m, 4H), 3.97–3.94 (t, 3J (H,H) = 4.4 Hz, 2H), 3.81–3.77 (m, 4H), 3.62–3.58 (m, 4H), 3.55–3.51 (m, 4H), 3.50–3.46 (m, 8H), 3.41–3.92 (m, 4H), 3.37–3.35 (m, 2H), 3.13 (br s, 1H), 2.20 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 154.26 (2C), 144.76, 132.84, 129.80, 127.78, 126.64 (2C), 125.11 (2C), 114.51 (2C), 105.64 (2C), 72.49, 70.76 (2C), 70.52, 70.49, 70.48, 70.45, 70.38, 70.16, 69.63 (2C), 69.37, 68.46, 67.83 (2C), 61.43, 21.45. HRMS Calcd for $\text{C}_{33}\text{H}_{46}\text{O}_{12}\text{S}$: 666.2710. Found: 666.2693.

Scheme S3. Synthesis of DNP Azide Derivative **7c**.




The tosylate **S2** (780 mg, 1.17 mmol) and NaN_3 (130 mg, 2.00 mmol) were dissolved in dry DMF (50 mL). The mixture was stirred at 60 °C for 3 d. After cooling, the solvent was removed in vacuo, and the crude material was filtered through a plug of silica, eluting with Me_2CO . A brown oil was obtained and found to be pure **7c** (599 mg, 95%). **7c**: MS (FAB+): m/z (rel intensity) = 537 (M^+ , 100%), 510 (28). ^1H NMR (400 MHz, CDCl_3): δ 7.79 (br d, 3J (H,H) = 8.4 Hz, 2H), 7.27 (br t, 3J (H,H) = 8.4 Hz, 2H), 6.75 (br d, 3J (H,H) = 8.4 Hz, 2H), 4.20–4.18 (m, 4H), 3.91–3.88 (m, 4H), 3.73–3.70 (m, 4H), 3.64–3.58 (m, 8H), 3.56–3.53 (m, 8H), 3.50–3.48 (m, 2H), 3.27–3.24 (m, 2H), 3.09 (br s, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 154.30, 154.27, 126.71, 126.70, 125.13, 125.11, 114.60, 114.55, 105.70, 105.66, 72.54, 70.89, 70.81, 70.66, 70.58, 70.55, 70.50, 70.48, 70.16, 69.91, 69.71 (2C), 67.86 (2C), 61.47, 50.58. HRMS Calcd for $\text{C}_{26}\text{H}_{39}\text{N}_3\text{O}_9$: 537.2686. Found: 537.2684.

Scheme S4. Synthesis of DNP Azidoalkyne Derivative **8a**.



Compound **7a** (380 mg, 1.05 mmol) was dissolved in dry DMF (30 mL) and treated with NaH (60 mg, 2.10 mmol). After the evolution of gas ceased (~30 min), propargyl bromide (230 μ L of 80% wt solution in PhMe, 2.10 mmol) was added via a syringe. The mixture was left to stir at 23 °C for 3 d. Solvent was removed in vacuo and the crude mixture was subjected to column chromatography (CH₂Cl₂/MeOH = 95/5). The first fraction contained **8a** as a brown oil (350 mg, 86%). **8a**: ¹H NMR (400 MHz, CDCl₃): δ 7.88 (d, ³*J* (H,H) = 8.4 Hz, 1H), 7.87 (d, ³*J* (H,H) = 8.4 Hz, 1H), 7.37 (t, ³*J* (H,H) = 8.4 Hz, 2H), 6.85 (d, ³*J* (H,H) = 8.4 Hz, 1H), 6.85 (d, ³*J* (H,H) = 8.4 Hz, 1H), 4.29–4.27 (m, 4H), 4.22 (d, ⁴*J* (H,H) = 2.5 Hz, 2H), 3.99–3.96 (m, 4H), 3.82–3.77 (m, 6H), 3.41 (t, ³*J* (H,H) = 5.0 Hz, 4H), 2.44 (t, ⁴*J* (H,H) = 2.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 154.35, 154.26, 126.77 (2C), 125.20, 125.12, 114.77, 114.58, 105.79, 105.75, 79.69, 74.66, 70.77, 70.37, 69.84 (2C), 69.22, 67.96, 67.94, 58.47, 50.82.


Scheme S5. Synthesis of DNP Azidoalkyne Derivative **8c**.



Compound **7c** (599 mg, 1.12 mmol) was dissolved in dry DMF (25 mL) and treated with NaH (48 mg, 2.00 mmol). After the evolution of gas ceased (~30 min), propargyl bromide (334 μ L of 80% wt solution in PhMe, 3.00 mmol) was added via a syringe. The mixture was stirred for 2 d at 23 °C and subsequently quenched with MeOH (2.0 mL). Solvents


were removed in vacuo and the resulting crude mixture was filtered through a plug of silica (eluting with Me₂CO), and subsequently subjected to chromatography (CH₂Cl₂/Me₂CO = 75/25) to provide pure **8c** as the second fraction (300 mg, 47%). **8c**: MS (FAB+): *m/z* (rel intensity) = 575 (M⁺, 94%), 548 (28), 537 (100), 510 (30). ¹H NMR (500 MHz, CDCl₃): δ 7.86 (br d, ³*J* (H,H) = 8.4 Hz, 2H), 7.34 (t, ³*J* (H,H) = 8.4 Hz, 2H), 6.83 (d, ³*J* (H,H) = 8.4 Hz, 2H), 4.29 (t, ³*J* (H,H) = 5.0 Hz, 4H), 4.18 (d, ⁴*J* (H,H) = 2.5 Hz, 2H), 3.99 (t, ³*J* (H,H) = 5.0 Hz, 4H), 3.81–3.77 (m, 4H), 3.71–3.67 (m, 4H), 3.67–3.63 (m, 14H), 3.34 (t, ³*J* (H,H) = 5.0 Hz, 4H), 2.41 (t, ⁴*J* (H,H) = 2.5 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 154.25 (2C), 126.69 (2C), 124.95 (2C), 114.53 (2C), 105.58 (2C), 79.58, 74.37, 70.90, 70.88, 70.68, 70.62 (2C), 70.60, 70.54, 70.51, 70.29, 69.89, 69.71 (2C), 69.00, 67.83 (2C), 58.27, 50.56. HRMS Calcd for C₂₉H₄₁N₃O₉: 575.2842. Found: 575.2826.

Scheme S6. Synthesis of DNP Diyne Derivative **9a**.




Diol **6a** (1.12 g, 3.33 mmol) was dissolved in dry DMF (25 mL) and treated with NaH (192 mg, 8.00 mmol). After the evolution of gas ceased (~30 min), propargyl bromide (2.2 mL of 80% wt solution in PhMe, 20.0 mmol) was added via a syringe. The mixture was stirred at 23 °C for 3 d. MeOH (2.0 mL) was added and the solvents were removed in vacuo. Crude brown oil was filtered through a plug of silica, eluting with Me₂CO, to provide pure **9a** (840 mg, 61%) as a dark yellow oil which solidifies on standing, mp 85–88 °C. **9a**: MS (FAB+): *m/z* (rel intensity) = 412 (M⁺, 100%), 374 (16). ¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, ³*J* (H,H) = 8.4 Hz, 2H), 7.21 (t, ³*J* (H,H) = 8.4 Hz, 2H), 6.68 (d, ³*J* (H,H) = 8.4 Hz, 2H), 4.11–4.09 (m, 4H), 4.06 (d, ⁴*J* (H,H) = 2.4 Hz, 4H), 3.81–3.79 (m, 4H), 3.65–3.62 (m, 4H), 3.58–3.55 (m, 4H), 2.40 (t, ⁴*J* (H,H) = 2.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 154.21, 126.64, 125.08, 114.53, 105.64, 79.66, 74.80, 70.56, 69.66, 69.06, 67.80, 58.28. HRMS Calcd for C₂₄H₂₈O₆: 412.1886. Found: 412.1875.

Scheme S7. Synthesis of DNP Diyne Derivative **9c**.




Diol **6c** (1.28 g, 2.50 mmol) was dissolved in dry DMF (25 mL) and treated with NaH (156 mg, 6.50 mmol). After the evolution of gas ceased (~30 min), propargyl bromide (1.8 mL of 80% wt solution in PhMe, 16.0 mmol) was added via a syringe. The mixture was stirred at 23 °C for 3 d. MeOH (2.0 mL) was added and the solvents were removed in vacuo. The crude brown oil was filtered through a plug of silica, eluting with Me₂CO, to provide pure **9c** (1.39 g, 95%) as a brown oil. **9c**: MS (FAB+): m/z (rel intensity) = 588 (M^+ , 100%), 391 (33). ¹H NMR (500 MHz, CDCl₃): δ 7.84 (d, ³ J (H,H) = 8.5 Hz, 2H), 7.33 (t, ³ J (H,H) = 8.4 Hz, 2H), 6.83 (d, ³ J (H,H) = 8.4 Hz, 2H), 4.29–4.27 (m, 4H), 4.17 (d, ⁴ J (H,H) = 2.4 Hz, 4H), 4.00–3.95 (m, 4H), 3.80–3.78 (m, 4H), 3.70–3.67 (m, 4H), 3.67–3.63 (m, 16H), 2.41 (t, ⁴ J (H,H) = 2.4 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 154.22, 126.65, 124.98, 114.51, 105.55, 79.56, 74.44, 70.89, 70.60, 70.53, 70.51, 70.29, 69.72, 69.00, 67.81, 58.29. HRMS Calcd for C₃₂H₄₄O₁₀: 588.2934. Found: 588.2942.

Scheme S8. Attempted Synthesis of Catenane **1a** · 4PF₆.



The DNP derivative **8a** (9.2 mg, 0.024 mmol), **CBPQT** · 4PF₆ (22.0 mg, 0.02 mmol), and CuI (2.0 mg, 0.01 mmol) were dissolved in CD₃CN (0.6 mL) and transferred into an NMR tube. The purple solution was left at 23 °C for 2 d. After this time, ¹H NMR spectroscopy and FAB MS showed no sign of formation of **1a** · 4PF₆. Performing the reaction with a CuSO₄ · 5H₂O / ascorbic acid catalyst mixture gave identical results.


Scheme S9. Synthesis of Catenane **1c** · 4PF₆.



The DNP derivative **8c** (34.5 mg, 0.06 mmol), **CBPQT** · 4PF₆ (44.0 mg, 0.04 mmol), and CuI (11.5 mg, 0.06 mmol) were suspended in CD₃CN (0.6 mL) and transferred into an NMR tube. The purple solution was allowed to stand at 23 °C for 3 d. After this time, the ¹H NMR spectroscopy showed peaks consistent with the presence of **1c** · 4PF₆. The reaction mixture was filtered through a plug of silica (gradient elution: Me₂CO → 2% solution of NH₄PF₆ in Me₂CO). Purple fractions were collected, concentrated to a minimum volume and the crude catenane **1c** · 4PF₆ was precipitated by the addition of H₂O. After filtration and drying, this crude material was analyzed and showed to contain **CBPQT** · 4PF₆ and the desired [2]catenane **1c** · 4PF₆. The crude mixture was dissolved in minimum amount of Me₂CO and hexane was added dropwise until precipitation of **CBPQT** · 4PF₆ occurred. Removal of the solvent from the supernatant provided pure **1c** · 4PF₆ (15 mg, 23%) as a purple solid, mp 199–201 °C with decomp. **1c** · 4PF₆: MS (ESI): *m/z* (rel intensity) = 1530 ([**1c** · 3PF₆]⁺, 8%), 692 ([**1c** · 2PF₆]²⁺, 100), 413 ([**1c** · PF₆]³⁺, 45). ¹H NMR (500 MHz, DMF-*d*₇, 270 K): δ 9.73 (br d, 1H, α-CBPQT⁴⁺-H), 9.48 (d, ³*J* (H,H) = 6.5 Hz, 1H, α-CBPQT⁴⁺-H), 9.46 (d, ³*J* (H,H) = 6.6 Hz, 1H, α-CBPQT⁴⁺-H), 9.44–9.34 (br m, 2H, α-CBPQT⁴⁺-H), 9.32 (d, ³*J* (H,H) = 6.8 Hz, 1H, α-CBPQT⁴⁺-H), 9.28 (d, ³*J* (H,H) = 6.7 Hz, 1H, α-CBPQT⁴⁺-H), 8.81 (br s, 1H, α-CBPQT⁴⁺-H), 8.31–8.09 (m, 8H, β-CBPQT⁴⁺-H), 7.85 (br m, 2H, aryl-CBPQT⁴⁺-H), 7.82 (br s, 2H, aryl-CBPQT⁴⁺-H), 7.72 (br s, 2H, aryl-CBPQT⁴⁺-H), 7.62 (br s, 2H, aryl-CBPQT⁴⁺-H), 7.46 (s, 1H, triazole-H), 6.29 (d, ³*J* (H,H) = 7.9 Hz, 1H, DNP aryl-H *o*-O), 6.10–5.91 (m, 11H, DNP aryl-H *o*-O, DNP aryl-H *m*-O, and CBPQT⁴⁺ benzyl-H), 4.18–2.69 (m, 32H), 3.03 (s, 2H, propargyl-H), 2.54 (d, ³*J* (H,H) = 7.7 Hz, 1H, DNP aryl-H *p*-O), 2.53 (d, ³*J* (H,H) = 8.0 Hz, 1H, DNP


aryl-H *p*-O). HRMS Calcd for C₆₅H₇₃N₇O₉P₂F₁₂ ([**1c** · 2PF₆]²⁺): 692.7389. Found: 692.7350.

Scheme S10. Attempted Synthesis of Catenane **2a** · 4PF₆.



The DNP derivative **9a** (50.0 mg, 0.12 mmol), **CBPQT** · 4PF₆ (44.0 mg, 0.04 mmol), and Cu(OAc)₂ · H₂O (40.0 mg, 0.20 mmol) were dissolved in MeCN (30 mL). The deeply bluish-purple solution was stirred at 23 °C for 2 d. The solvent was removed in vacuo, and the crude purple solid was subjected to column chromatography on silica (Me₂CO → 2% solution of NH₄PF₆ in Me₂CO). Several fractions were collected, concentrated to a small volume, and precipitated by addition of cold H₂O. None of the materials isolated by filtration contained any evidence for the presence of **2a** · 4PF₆ (by ¹H NMR spectroscopy and FAB MS). Additionally, although **2a** · 4PF₆ was expected to be purple, all of the collected fractions were either colorless or pale yellow.


Scheme S11. Improved Synthesis of Catenane **2b** · 4PF₆.



The DNP derivative **9b** (60.0 mg, 0.12 mmol), **CBPQT** · 4PF₆ (44.0 mg, 0.04 mmol), and Cu(OAc)₂ · H₂O (40.0 mg, 0.20 mmol) were dissolved in MeCN (30 mL). The deeply bluish-purple solution was stirred at 23 °C for 2 d. The solvent was removed in vacuo, and

the crude purple solid was subjected to column chromatography on silica ($\text{Me}_2\text{CO} \rightarrow 2\%$ solution of NH_4PF_6 in Me_2CO). Purple fractions were collected and reduced to minimal volume. Cold H_2O was added to precipitate the purple solid. After filtration and drying, 58 mg (97%) of **2b** \cdot 4PF_6 was obtained. The spectroscopic data for this sample were identical to one previously reported.^{S6} The amount of **2b** \cdot 4PF_6 prepared allowed the collection of ^{13}C NMR spectrum. **2b** \cdot 4PF_6 : ^{13}C NMR (125 MHz, CD_3CN): δ 151.00, 145.12, 144.37, 136.48, 131.29, 131.07, 128.02, 125.92, 124.45, 124.35, 108.27, 104.12, 70.75, 70.54, 70.12, 69.70, 69.48, 68.25, 67.84, 57.89.

Scheme S12. Synthesis of Catenane **2c** \cdot 4PF_6 .



The DNP derivative **9c** (72.0 mg, 0.12 mmol), **CBPQT** \cdot 4PF_6 (44.0 mg, 0.04 mmol), and $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$ (40.0 mg, 0.20 mmol) were dissolved in MeCN (30 mL). The deeply bluish-purple solution was stirred at 23 °C for 2 d. The solvent was removed in vacuo, and the crude purple solid was subjected to column chromatography on silica ($\text{Me}_2\text{CO} \rightarrow 1\%$ solution of NH_4PF_6 in Me_2CO). Purple fractions were collected and concentrated to dryness. Cold H_2O was added to precipitate the purple solid. After filtration and drying, this crude material was analyzed and showed to contain **CBPQT** \cdot 4PF_6 and the desired **2c** \cdot 4PF_6 . The crude mixture was dissolved in minimal amount of acetone and hexane was added dropwise until precipitation of **CBPQT** \cdot 4PF_6 occurred. Removal of the solvent from the supernatant provided pure **2c** \cdot 4PF_6 (35 mg, 52%) as a purple solid, mp $>230^\circ\text{C}$ without decomp. **2c** \cdot 4PF_6 : MS (ESI): m/z (rel intensity) = 1541 ($[\text{2c} \cdot 3\text{PF}_6]^+$, 1%), 698 ($[\text{2c} \cdot 2\text{PF}_6]^{2+}$, 62), 563 (100), 417 ($[\text{2c} \cdot \text{PF}_6]^{3+}$, 31). ^1H NMR (500 MHz, CD_3CN): δ 9.01 (br s, 2H, α -CBPQT $^{4+}$ -H), 8.86 (br s, 4H, α -CBPQT $^{4+}$ -H), 8.65 (br s, 2H, α -CBPQT $^{4+}$ -H), 8.02 (br s, 8H, β -CBPQT $^{4+}$ -H), 7.34 (br s, 8H, aryl-CBPQT $^{4+}$ -H), 6.27 (d, $^3J(\text{H,H}) = 7.8$

Hz, 2H, DNP aryl-H *o*-O), 6.02 (t, 3J (H,H) = 8.0 Hz, 2H, DNP aryl-H *m*-O), 5.74 (br s, 8H, CBPQT⁴⁺ benzyl H), 4.31 (m, 4H), 4.17 (m, 4H), 4.02 (m, 4H), 3.89 (m, 4H), 3.85 (s, 4H, propargyl-H), 3.73 (m, 2H), 3.56 (m, 2H), 3.40 (m, 2H), 3.19 (m, 2H), 2.50 (br s, 2H, DNP aryl-H *p*-O). HRMS Calcd for C₆₈H₇₄N₄O₁₀P₂F₁₂ ([**6** · 2PF₆]²⁺): 698.2350. Found: 698.2326.

X-Ray Diffraction: Data Collection and Refinement Parameters

[9a \subset CBPQT] \cdot 4PF₆: C₆₀H₆₀F₂₄N₄O₆P₄, crystal size 0.20 \times 0.20 \times 0.15 mm³, space group $P\bar{1}$, scan range $8.0 < 2\theta < 56.6^\circ$, $T = 100(2)$ K, $a = 10.163(3)$, $b = 12.669(4)$, $c = 14.245(5)$ Å, $\alpha = 99.963(4)$, $\beta = 107.120(3)$, $\gamma = 112.522(3)$, $V = 1531.9(9)$ Å³, $Z = 1$, $\rho_{\text{calcd}} = 1.640$ gcm⁻³, $\mu(\text{MoK}\alpha) = 0.253$ mm⁻¹, 7331 unique reflections, of which 5083 were taken as observed [$I > 2\sigma(I)$], $R(F) = 0.059$, $wR(F^2) = 0.155$ (all data).

1b \cdot 4PF₆: C₇₃H₈₃F₂₄N₁₃O₇P₄, crystal size 0.60 \times 0.40 \times 0.05 mm³, space group $P\bar{1}$, scan range $7.8 < 2\theta < 53.1^\circ$, $T = 100(2)$ K, $a = 15.304(7)$, $b = 15.316(7)$, $c = 21.776(14)$ Å, $\alpha = 95.059(7)$, $\beta = 106.489(7)$, $\gamma = 116.953(5)$, $V = 4220(4)$ Å³, $Z = 2$, $\rho_{\text{calcd}} = 1.444$ gcm⁻³, $\mu(\text{MoK}\alpha) = 0.201$ mm⁻¹, 17307 unique reflections, of which 7251 were taken as observed [$I > 2\sigma(I)$], $R(F) = 0.076$, $wR(F^2) = 0.239$ (all data).

2b \cdot 4PF₆: C₇₆H₈₄F₂₄N₁₀O₈P₄, crystal size 0.50 \times 0.40 \times 0.20 mm³, space group $P\bar{1}$, scan range $8.4 < 2\theta < 59.7^\circ$, $T = 100(2)$ K, $a = 13.690(2)$, $b = 13.848(2)$, $c = 24.046(4)$ Å, $\alpha = 84.815(2)$, $\beta = 85.732(2)$, $\gamma = 67.626(2)$, $V = 4194.3(11)$ Å³, $Z = 1$, $\rho_{\text{calcd}} = 1.461$ gcm⁻³, $\mu(\text{MoK}\alpha) = 0.203$ mm⁻¹, 23132 unique reflections, of which 17155 were taken as observed [$I > 2\sigma(I)$], $R(F) = 0.076$, $wR(F^2) = 0.222$ (all data).

2c \cdot 4PF₆: C₈₀H₉₂F₂₄N₁₃O₁₀P₄, crystal size 0.60 \times 0.30 \times 0.10 mm³, space group $P\bar{1}$, scan range $7.8 < 2\theta < 56.5^\circ$, $T = 100(2)$ K, $a = 14.021(3)$, $b = 14.121(3)$, $c = 22.210(5)$ Å, $\alpha = 94.628(2)$, $\beta = 93.400(2)$, $\gamma = 93.554(3)$, $V = 4365.5(17)$ Å³, $Z = 2$, $\rho_{\text{calcd}} = 1.470$ gcm⁻³, $\mu(\text{MoK}\alpha) = 0.200$ mm⁻¹, 20861 unique reflections, of which 13530 were taken as observed [$I > 2\sigma(I)$], $R(F) = 0.085$, $wR(F^2) = 0.275$ (all data).




Figure S1. Unit cell contents of [2]pseudorotaxane [9a ⊂ CBPQT]⁴⁺. Donor rings shown in red, acceptor rings in blue, PF₆[−] counterions in gray. Aside from the remaining PF₆[−] counterions, hydrogen atoms and solvent molecules were omitted for clarity.




Figure S2. Section of the packing diagram of [2]pseudorotaxane [9a ⊂ CBPQT]⁴⁺, viewed down the crystallographic *a* axis. Donor rings shown in red, acceptor rings in blue. Aside from PF₆[−] counterions, hydrogen atoms and solvent molecules were omitted for clarity.




Figure S3. Unit cell contents of [2]catenane **1b**⁴⁺. Donor rings shown in red, acceptor rings in blue, bridging PF₆[−] counterions in gray. Aside from the remaining PF₆[−] counterions, hydrogen atoms and solvent molecules were omitted for clarity.




Figure S4. Section of the packing diagram of [2]catenane **1b**⁴⁺. Donor rings shown in red, acceptor rings in blue. Aside from PF₆[−] counterions, hydrogen atoms and solvent molecules were omitted for clarity.




Figure S5. Unit cell contents of [2]catenane **2b**⁴⁺. Donor rings shown in red, acceptor rings in blue. Aside from PF₆[−] counterions, hydrogen atoms and solvent molecules were omitted for clarity.




Figure S6. Section of the packing diagram of [2]catenane **2b**⁴⁺. Donor rings shown in red, acceptor rings in blue. Aside from PF₆[−] counterions, hydrogen atoms and solvent molecules were omitted for clarity.




Figure S7. Unit cell contents of [2]catenane **2c**⁴⁺. Donor rings shown in red, acceptor rings in blue. Aside from PF₆[−] counterions, hydrogen atoms and solvent molecules were omitted for clarity.




Figure S8. Section of the packing diagram of [2]catenane **2c**⁴⁺. Donor rings shown in red, acceptor rings in blue. Aside from PF₆[−] counterions, hydrogen atoms and solvent molecules were omitted for clarity.

Partial VT-NMR spectra of [2]catenanes **1b,c** · 4PF₆ and **2b,c** · 4PF₆




Figure S9. VT-NMR spectra of **1b** · 4PF₆ (DMF-*d*₇).




Figure S10. VT-NMR spectra of **1c** · 4PF₆ (DMF-*d*₇).




Figure S11. VT-NMR spectra of **2b** · 4PF₆ (DMF- d_7).




Figure S12. VT-NMR spectra of **2c** · 4PF₆ (DMF- d_7).

References

- (S1) Asakawa, M.; Dehaen, W.; L'abbé, G.; Menzer, S.; Nouwen, J.; Raymo, F. M.; Stoddart, J. F.; Williams, D. J. *J. Org. Chem.* **1996**, *61*, 9591–9595.
- (S2) Amabilino, D. B.; Anelli, P.-L.; Ashton, P. R.; Brown, G. R.; Córdova, E.; Godínez, L. A.; Hayes, W.; Kaifer, A. E.; Philp, D.; Slawin, A. M. Z.; Spencer, N.; Stoddart, J. F.; Tolley, M. S.; Williams, D. J. *J. Am. Chem. Soc.* **1995**, *117*, 11142–11170.
- (S3) Ashton, P. R.; Huff, J.; Menzer, S.; Parsons, I. W.; Preece, J. A.; Stoddart, J. F.; Tolley, M. S.; White, A. J. P.; Williams, D. J. *Chem. Eur. J.* **1996**, *2*, 31–44.
- (S4) Collier, C. P.; Jeppesen, J. O.; Liu, Y.; Perkins, J.; Wong, E. W.; Heath, J. R.; Stoddart, J. F. *J. Am. Chem. Soc.* **2001**, *123*, 12632–12641.
- (S5) Liu, Y.; Saha, S.; Vignon, S. A.; Flood, A. H.; Stoddart, J. F. *Synthesis* **2005**, 3437–3455.
- (S6) Miljanić, O. Š.; Dichtel, W. R.; Mortezaei, S.; Stoddart, J. F. *Org. Lett.* **2006**, *8*, 4835–4838.

Full References from the Manuscript

- (6j) Green, J. E.; Choi, J. W.; Boukai, A.; Bunimovich, Y.; Johnston-Halprin, E.; DeIonno, E.; Luo, Y.; Sheriff, B. A.; Xu, K.; Shin, Y. S.; Tseng, H.-R.; Stoddart, J. F.; Heath, J. R. *Nature* **2007**, *445*, 414–417.
- (11c) Anelli, P.-L.; Masumi Asakawa, M.; Ashton, P. R.; Bissell, R. A.; Clavier, G.; Górski, R.; Kaifer, A. E.; Langford, S. J.; Mattersteig, G.; Menzer, S.; Philp, D.; Slawin, A. M. Z.; Spencer, N.; Stoddart, J. F.; Tolley, M. S.; Williams, D. J. *Chem.–Eur. J.* **1997**, *3*, 1113–1135.

- (12c) Anelli, P.-L.; Ashton, P. R.; Ballardini, R.; Balzani, V.; Delgado, M.; Gandolfi, M. T.; Goodnow, T. T.; Kaifer, A. E.; Philp, D.; Pietraszkiewicz, M.; Prodi, L.; Reddington, M. V.; Slawin, A. M. Z.; Spencer, N.; Stoddart, J. F.; Vicent, C.; Williams, D. J. *J. Am. Chem. Soc.* **1992**, *114*, 193–218.
- (14) Ashton, P. R.; Brown, C. L.; Chrystal, E. J. T.; Goodnow, T. T.; Kaifer, A. E.; Parry, K. P.; Philp, D.; Slawin, A. M. Z.; Spencer, N.; Stoddart, J. F.; Williams, D. J. *J. Chem. Soc., Chem. Commun.* **1991**, 634–639.
- (15c) Asakawa, M.; Ashton, P. R.; Balzani, V.; Credi, A.; Hamers, C.; Mattersteig, G.; Montalti, M.; Shipway, A. N.; Spencer, N.; Stoddart, J. F.; Tolley, M. S.; Venturi, M.; White, A. J. P.; Williams, D. J. *Angew. Chem. Int. Ed.* **1998**, *37*, 333–337.
- (30a) Amabilino, D. B.; Anelli, P.-L.; Ashton, P. R.; Brown, G. R.; Córdova, E.; Godínez, L. A.; Hayes, W.; Kaifer, A. E.; Philp, D.; Slawin, A. M. Z.; Spencer, N.; Stoddart, J. F.; Tolley, M. S.; Williams, D. J. *J. Am. Chem. Soc.* **1995**, *117*, 11142–11170.
- (33) Asakawa, M.; Ashton, P. R.; Boyd, S. E.; Brown, C. L.; Gillard, R. E.; Kocian, O.; Raymo, F. M.; Stoddart, J. F.; Tolley, M. S.; White, A. J. P.; Williams, D. J. *J. Org. Chem.* **1997**, *62*, 26–37.
- (48b) Ashton, P. R.; Balzani, V.; Credi, A.; Kocian, O.; Pasini, D.; Prodi, L.; Spencer, N.; Stoddart, J. F.; Tolley, M. S.; Venturi, M.; White, A. J. P.; Williams, D. J. *Chem.–Eur. J.* **1998**, *4*, 590–607.
- (49a) Liu, Y.; Flood, A. H.; Bonvallett, P. A.; Vignon, S. A.; Northrop, B. H.; Tseng, H. R.; Jeppesen, J. O.; Huang, T. J.; Brough, B.; Baller, M.; Magonov, S.; Solares, S. D.; Goddard, W. A.; Ho, C. M.; Stoddart, J. F. *J. Am. Chem. Soc.* **2005**, *127*, 9745–9759.
- (49b) Huang, T. J.; Brough, B.; Ho, C.-M.; Liu, Y.; Flood, A. H.; Bonvallet, P. A.; Tseng, H.-R.; Stoddart, J. F.; Baller, M.; Magonov, S. *Appl. Phys. Lett.* **2004**, *85*, 5391–5393.